Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence

Phase 2 Unknown 30 enrolled First Affiliated Hospital Xi'an Jiaotong University Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

A single-arm, open-label clinical trial to assess the effects and safety of anlotinib hydrochloride combined with transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma(HCC) patients at high risk of post surgery recurrence.

Timeline

Start: 2020-04-23
Primary completion: 2023-02
Completion: 2023-09

Publications

Wang Z, Zhang L, Zheng X, Zhang D, Yang X, Xu K, Tao J, Song X, Ma J, Wu Z. Adjuvant anlotinib plus TACE in hepatocellular carcinoma with postoperative high-risk recurrence: a single-arm, multi-center, phase II study. Clin Transl Oncol. 2026 Jun;28(6):2198-2207. doi: 10.1007/s12094-025-04160-0. Epub 2026 Jan 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	12 mg	Oral

Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence

Summary

Timeline

Publications

Drugs

Indications